phenyl (methoxy-L-valinyl)phosphorochloridate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: phenyl (methoxy-L-valinyl)phosphorochloridate
• 英文别名: methyl (2R)-2-[[chloro(phenoxy)phosphoryl]amino]-3-methylbutanoate
• 化学式: C₁₂H₁₇ClNO₄P
• 分子量: 305.698
• InChiKey: PNQKVXYESRZLML-AMIJKRQISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  19
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  phenyl (methoxy-L-valinyl)phosphorochloridate 、 dioxolanethymidine 在 N-甲基咪唑 作用下， 以 四氢呋喃 为溶剂， 反应 8.0h， 生成 methyl (2R)-3-methyl-2-[[[(2R,4R)-4-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-1,3-dioxolan-2-yl]methoxy-phenoxy-phosphoryl]amino]butanoate
  参考文献：
  名称：

  Phosphoramidate and phosphate prodrugs of (−)-β-d-(2R,4R)-dioxolane-thymine: Synthesis, anti-HIV activity and stability studies

  摘要：

  A series of phosphoramidate and phosphate prodrugs of DOT were synthesized via dichlorophosphate or H-phosphonate chemistry and evaluated for their anti-HIV activity against LAI M 184V mutants in PBM cells as well as for their cytotoxicity. The antiviral and cytotoxic profiles of the prodrugs were compared with that of the parent compound (DOT), and it was found that four aryl phosphoramidates 5, 18, 20, and 26 showed a significant enhancement (8- to 12-fold) in anti-HIV activity without cytotoxicity. Chemical stability of these prodrugs was evaluated in phosphate buffer at pH values of biological relevance (i.e., pH 2.0 and 7.4). Enzymatic hydrolysis was also studied in esterase or lipase in buffer solution. Chemical stability studies indicate that the phosphoramidates have good chemical stability at pH 2.0 and at pH 7.4 phosphate buffer. Phosphoramidate prodrugs were hydrolyzed in vitro by esterase or lipase and found to be better substrates for lipases than for esterases. 1,3-Diol cyclic phosphates showed potent anti-HIV activity without increasing the cytotoxicity compared with that of DOT and have good chemical and enzymatic stability. Long-chain lipid phosphates, although showed potent anti-HIV activity, exhibited increased cytotoxicity. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2005.11.008
• 作为产物：
  描述：

  D-缬氨酸 在 氯化亚砜 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 生成 phenyl (methoxy-L-valinyl)phosphorochloridate
  参考文献：
  名称：

  氨基磷酸酯ProTide技术的应用显着提高了碳环腺苷衍生物的抗病毒效力。

  摘要：

  我们报告了氨基磷酸酯原核苷酸（ProTide）技术在抗病毒剂碳环L-d4A（L-Cd4A）中的应用。L-Cd4A的苯基甲基丙氨酸基母体ProTide是通过格利雅（Grignard）介导的磷酰氯反应制备的，得到的化合物具有显着改善的抗HIV（2600倍）和HBV活性。我们描述了ProTide的芳基，酯和氨基酸区域的修饰，以及这些变化如何影响抗病毒活性和代谢稳定性。注意到针对HIV和HBV的SAR分别且不同。另外，由D-核苷D-Cd4A和双脱氧类似物L-CddA和D-CddA制备ProTide。与母体药物相比，这些化合物显示出更适度的效能改善。综上所述，当将ProTide方法应用于L-Cd4A时，在体外的效价提高了9000倍，非常成功，抗HIV的能力提高了。为了临床前候选人的选择，我们使用食蟹猴肝脏和肠道S9馏分进行了代谢稳定性研究。

  DOI：

  10.1021/jm060776w

文献信息

• Design and synthesis of vidarabine prodrugs as antiviral agents
  作者：Wei Shen、Jae-Seung Kim、Phillip E. Kish、Jie Zhang、Stefanie Mitchell、Brian G. Gentry、Julie M. Breitenbach、John C. Drach、John Hilfinger

  DOI：10.1016/j.bmcl.2008.12.031

  日期：2009.2

  5′-O-d- and l-amino acid derivatives and 5′-O-(d- and l-amino acid methyl ester phosphoramidate) derivatives of vidarabine (ara-A) were synthesized as vidarabine prodrugs. Some compounds were equi- or more potent in vitro than vidarabine against two pox viruses and their uptake by cultured cells was improved compared to the parent drug.

  合成了阿糖腺苷 (ara-A) 的5'- O - d - 和l - 氨基酸衍生物以及 5'- O -（d - 和l - 氨基酸甲酯氨基磷酸酯）衍生物作为阿糖腺苷前药。一些化合物在体外对抗两种痘病毒的效力与阿糖腺苷相当或更强，并且与母体药物相比，它们被培养细胞的吸收得到改善。
• Aryl Phosphoramidates of 5-Phospho Erythronohydroxamic Acid, A New Class of Potent Trypanocidal Compounds
  作者：Gian Filippo Ruda、Pui Ee Wong、Vincent P. Alibu、Suzanne Norval、Kevin D. Read、Michael P. Barrett、Ian H. Gilbert

  DOI：10.1021/jm1004754

  日期：2010.8.26

  survival and make it an attractive drug target for the development of new treatments against human African trypanosomiasis. 2,3-O-Isopropylidene-4-erythrono hydroxamate is a potent inhibitor of parasite Trypanosoma brucei 6-phosphogluconate dehydrogenase (6-PGDH), the third enzyme of the pentose phosphate pathway. However, this compound does not have trypanocidal activity due to its poor membrane permeability

  RNAi 和酶促研究表明，布氏锥虫中 6-磷酸葡萄糖酸脱氢酶 (6-PGDH)对寄生虫存活的重要性，使其成为开发针对人类非洲锥虫病的新疗法的有吸引力的药物靶点。2,3- O -Isopropylidene-4-erythrono hydroxamate 是寄生虫布氏锥虫的有效抑制剂6-磷酸葡萄糖酸脱氢酶 (6-PGDH)，戊糖磷酸途径的第三种酶。然而，由于其膜渗透性差，该化合物不具有杀锥虫活性。因此，我们之前已经报道了一种前药方法，通过将磷酸基团转化为带电荷较少的磷酸前药来提高该抑制剂的抗寄生虫活性。前药的活性似乎取决于它们在磷酸盐缓冲液中的稳定性。在这里，我们成功地进一步扩展了 2,3- O的芳基氨基磷酸酯前药的开发。-isopropylidene-4-erythrono hypoxamate 通过合成一个小的氨基磷酸酯文库并在各种测定中评估它们的生物活性和稳定性。一些化合物显示出较高的
• Application of Phosphoramidate ProTide Technology Significantly Improves Antiviral Potency of Carbocyclic Adenosine Derivatives
  作者：Christopher McGuigan、Alshaimaa Hassan-Abdallah、Sheila Srinivasan、Yikang Wang、Adam Siddiqui、Susan M. Daluge、Kristjan S. Gudmundsson、Huiqiang Zhou、Ed W. McLean、Jennifer P. Peckham、Thimysta C. Burnette、Harry Marr、Richard Hazen、Lynn D. Condreay、Lance Johnson、Jan Balzarini

  DOI：10.1021/jm060776w

  日期：2006.11.30

  phosphoramidate pronucleotide (ProTide) technology to the antiviral agent carbocyclic L-d4A (L-Cd4A). The phenyl methyl alaninyl parent ProTide of L-Cd4A was prepared by Grignard-mediated phosphorochloridate reaction and resulted in a compound with significantly improved anti-HIV (2600-fold) and HBV activity. We describe modifications of the aryl, ester, and amino acid regions of the ProTide and how these changes

  我们报告了氨基磷酸酯原核苷酸（ProTide）技术在抗病毒剂碳环L-d4A（L-Cd4A）中的应用。L-Cd4A的苯基甲基丙氨酸基母体ProTide是通过格利雅（Grignard）介导的磷酰氯反应制备的，得到的化合物具有显着改善的抗HIV（2600倍）和HBV活性。我们描述了ProTide的芳基，酯和氨基酸区域的修饰，以及这些变化如何影响抗病毒活性和代谢稳定性。注意到针对HIV和HBV的SAR分别且不同。另外，由D-核苷D-Cd4A和双脱氧类似物L-CddA和D-CddA制备ProTide。与母体药物相比，这些化合物显示出更适度的效能改善。综上所述，当将ProTide方法应用于L-Cd4A时，在体外的效价提高了9000倍，非常成功，抗HIV的能力提高了。为了临床前候选人的选择，我们使用食蟹猴肝脏和肠道S9馏分进行了代谢稳定性研究。
• Phosphoramidate and phosphate prodrugs of (−)-β-d-(2R,4R)-dioxolane-thymine: Synthesis, anti-HIV activity and stability studies
  作者：Yuzeng Liang、Janarthanan Narayanasamy、Raymond F. Schinazi、Chung K. Chu

  DOI：10.1016/j.bmc.2005.11.008

  日期：2006.4

  A series of phosphoramidate and phosphate prodrugs of DOT were synthesized via dichlorophosphate or H-phosphonate chemistry and evaluated for their anti-HIV activity against LAI M 184V mutants in PBM cells as well as for their cytotoxicity. The antiviral and cytotoxic profiles of the prodrugs were compared with that of the parent compound (DOT), and it was found that four aryl phosphoramidates 5, 18, 20, and 26 showed a significant enhancement (8- to 12-fold) in anti-HIV activity without cytotoxicity. Chemical stability of these prodrugs was evaluated in phosphate buffer at pH values of biological relevance (i.e., pH 2.0 and 7.4). Enzymatic hydrolysis was also studied in esterase or lipase in buffer solution. Chemical stability studies indicate that the phosphoramidates have good chemical stability at pH 2.0 and at pH 7.4 phosphate buffer. Phosphoramidate prodrugs were hydrolyzed in vitro by esterase or lipase and found to be better substrates for lipases than for esterases. 1,3-Diol cyclic phosphates showed potent anti-HIV activity without increasing the cytotoxicity compared with that of DOT and have good chemical and enzymatic stability. Long-chain lipid phosphates, although showed potent anti-HIV activity, exhibited increased cytotoxicity. (c) 2005 Elsevier Ltd. All rights reserved.